MediciNova says US patent office allows ibudilast–anti-PD-1 combo claims for glioblastoma treatment
I'm LongbridgeAI, I can summarize articles.MediciNova Inc. announced that the U.S. Patent and Trademark Office has allowed patent claims for MN-166 (ibudilast) combined with an anti-PD-1 immune checkpoint inhibitor for glioblastoma treatment. The patent covers dosing and administration parameters, with an expected expiration no earlier than September 2042. This expanded intellectual property supports MediciNova's combination-therapy strategy for MN-166 in oncology.
- MediciNova received a U.S. patent allowance covering MN-166 (ibudilast) combined with an anti-PD-1 immune checkpoint inhibitor for glioblastoma. * Patent terms extend to dosing and administration parameters; expected to expire no earlier than September 2042. * Expanded IP could support its combination-therapy strategy for MN-166 in oncology. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MediciNova Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606300800PRIMZONEFULLFEED9754084) on June 30, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)